Diabetic dogs rapidly form bilateral sugar cataracts within one year of diagnosis. Similar sugar cataracts also form in galactose‐fed dogs. Since topical KinostatTM has been shown to reverse initial cataract formation in young galactose‐fed dogs, we have conducted a proof of concept masked pilot study with 41 newly diagnosed dogs with diabetes mellitus (DM) to investigate whether KinostatTM can inhibit the progression of cataracts in a clinical setting. After obtaining owner consent to participate in the study, all dogs were randomly assigned a coded vial containing either KinostatTM or vehicle for 1 year with the contents of the vial (drug or placebo) masked from the examiners. Thirty dogs received the active agent while the remainder received the placebo vehicle. Owners were instructed to administer the agent 3 times daily to both eyes and compliance was monitored by recording each time of administration. Ocular examinations on dilated eyes conducted at the initial examination and at 1, 2, 3, 6, and 9 month intervals with slit lamp and indirect ophthalmoscopy indicated that KinostatTM is beneficial in arresting the onset and/or progression of cataracts in dogs with DM. The implications of this study for human sugar cataracts will also be discussed. Supported by NIH SBIR 1R43EY018013‐01A1 Commercial interest
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.